Beijing Strong Biotechnologies, Inc. announced that its wholly-owned subsidiary, Fuzhou Maixin Biotechnology Development Co., Ltd., recently completed the registration of two Class I medical instruments with the Market Supervision Administration of Fuzhou City. The specific products include a fully automatic nucleic acid extractor and a New York esophageal squamous cell carcinoma 1 (NY-ESO-1) antibody reagent (immunohistochemistry method). The registration of these products will enhance the company's overall competitiveness, improve market expansion capabilities, and have a positive impact on the company's future Operation, but will not have a significant impact on recent production, operation, and performance.
九强生物：全资子公司完成第一类医疗器械备案
Beijing Strong Biotechnologies, Inc.: Wholly-owned subsidiary completes registration of Class I medical instruments.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha
【November 2024】Has disney's predicament turned around? Pay attention to these 3 performance signals.
As the entertainment kingdom for nearly a century, Disney's status in Hollywood has gained prominence. Over 60 years of listing on the U.S. stock market, Disney